Eli Lilly (NYSE:LLY) traded higher Thursday after the pharmaceutical company reported third-quarter results ahead of Wall ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Eli Lilly and (NYSE:LLY) with a Overweight ...

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

Also looking to the future, Eli Lilly Chairman and CEO David A. Ricks stated, “We advanced orforglipron through four ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...